Cargando…
Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches
Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene. However, rare mutations such as G719X and S768I lack standard anti-EGFR targeted therapies. Understanding the structural differences between wild-type EGFR and these rare mutants is c...
Autores principales: | Wang, Jun-Ling, Liu, Ming-Sheng, Fu, Yu-Dong, Kan, Qiang-Bo, Li, Chun-Yan, Ma, Rong, Fang, Zhe-Wei, Liu, Hong-Xia, Li, Meng-Xian, Lv, Jia-Ling, Sang, Peng, Zhang, Chao, Li, Hong-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685407/ https://www.ncbi.nlm.nih.gov/pubmed/38035047 http://dx.doi.org/10.1515/biol-2022-0768 |
Ejemplares similares
-
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018) -
Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China
por: Wang, Jun-Ling, et al.
Publicado: (2022) -
A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2023) -
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
por: Watanabe, Masahiro, et al.
Publicado: (2017) -
Successful treatment of a patient with NSCLC carrying uncommon compound EGFR
G719X and S768I mutations using osimertinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2020)